VRAX Stock Analysis: Buy, Sell, or Hold?
VRAX - Virax Biolabs Group Limited Ordinary Shares
$3.19
-0.26 (-7.54%)
▼
5d:
+11.54%
30d:
+0.0%
90d:
+942.48%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Oct 01, 2026
Get Alerted When VRAX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
ℹ️ NEUTRAL: VRAX is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
ℹ️ NEUTRAL: VRAX is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: VRAX is currently trading at $3.19, which is considered fair relative to its 30-day fair value range of $2.74 to $3.59.
Technical Outlook: Technically, VRAX is in a strong uptrend. Immediate support is located at $2.71, while resistance sits at $4.29. Short-term momentum is weak, with the stock down 7.5% recently.
Market Sentiment: VRAX scores 23/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $25.00 (+683.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, VRAX is in a strong uptrend. Immediate support is located at $2.71, while resistance sits at $4.29. Short-term momentum is weak, with the stock down 7.5% recently.
Market Sentiment: VRAX scores 23/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $25.00 (+683.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$2.74 -
$3.59
Company Quality Score
40/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
44.7%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (23/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-7.5%)
- BULLISH: Trading 683.7% below Wall St target ($25.00)
- WARNING: Composite score 40/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.74 -
$3.59
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$2.71
Resistance Level
$4.29
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.53
Wall Street Target
$25.00
(+683.7%)
Revenue Growth (YoY)
684.9%
Share & Embed Analysis
Last updated: August 23, 2026 12:21 AM ET
Data refreshes hourly during market hours. Next update: 1:21 AM
Data refreshes hourly during market hours. Next update: 1:21 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VRAX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 58 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 57 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 27 SELL |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 54 HOLD |
